<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263364</url>
  </required_header>
  <id_info>
    <org_study_id>GIRODON PRTS 2015</org_study_id>
    <nct_id>NCT03263364</nct_id>
  </id_info>
  <brief_title>Genomic Screening for Hereditary Erythrocytosis and Related Diseases</brief_title>
  <acronym>GENRED</acronym>
  <official_title>Genomic Screening for Hereditary Erythrocytosis and Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unexplained polycythemias are rare diseases, and therefore, the collection of data inherent&#xD;
      to these diseases will not only improve their characterisation, but also allow stratification&#xD;
      according to the risks and the course of the disease. The objective of this project is to&#xD;
      constitute a database on the disease which will allow us to better understand it and in due&#xD;
      course improve its management.&#xD;
&#xD;
      The GENRED project thus bears uniquely on the collection of information, which will be&#xD;
      gathered throughout the usual management of patients for this type of disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Germline mutations that cause Hereditary Erythrocytosis/Idiopathic Erythrocytosis</measure>
    <time_frame>at baseline</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hereditary Erythrocytosis/Idiopathic Erythrocytosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hereditary Erythrocytosis/Idiopathic Erythrocytosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The characteristics of the patients included in the database will be described in terms of&#xD;
        numbers and percentages for qualitative variables and in terms of means and standard&#xD;
        deviations or medians and interquartile intervals for quantitative variables.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The first step will be to exclude acquired secondary (pulmonary, renal and cardiac) or&#xD;
        acquired primary (polycythemia vera due to JAK2 mutations) causes. The family history and&#xD;
        the determination of serum EPO levels are very useful in the decision regarding which&#xD;
        molecular tests should be performed first.&#xD;
&#xD;
          -  patients without absolute erythrocytosis (i.e. without an increased red cell mass&#xD;
             &gt;125% of mean predicted value, or if the haematocrit is &lt;60% in males or &lt;56% in&#xD;
             females.&#xD;
&#xD;
          -  erythrocytosis related to polycythemia vera according to the 2008 WHO (World Health&#xD;
             Organization) criteria&#xD;
&#xD;
          -  Secondary erythrocytosis related to an obvious cause (renal lesions, chronic lung or&#xD;
             heart diseases, endocrine lesions, miscellaneous tumours producing EPO, drugs such as&#xD;
             androgens, hepatic lesions…)&#xD;
&#xD;
          -  Low venous blood p50: the determination of p50 (percentage at which Hb is half&#xD;
             saturated with oxygen) is very helpful is establishing the presence of a haemoglobin&#xD;
             variant with high oxygen affinity or a rare 2,3-diphosphoglycerate (2,3-DPG)&#xD;
             deficiency. In such a situation, a specific HBB, HBA1 and HBA2 mutation will be&#xD;
             screened for using Sanger sequencing (these genes are not included in NGS analysis&#xD;
             because of redundancy of pseudogenes).&#xD;
&#xD;
        In order to rule out non-informative erythrocytosis cases, a form including mandatory&#xD;
        further tests must be filled in for a selection step. The required tests are: complete&#xD;
        blood counts&#xD;
&#xD;
          -  Blood electrolytes&#xD;
&#xD;
          -  Arterial and venous gazes&#xD;
&#xD;
          -  Serum erythropoietin dosage&#xD;
&#xD;
          -  Liver function tests&#xD;
&#xD;
          -  JAK2 mutations (both V617F and exon 12)&#xD;
&#xD;
          -  Bone marrow aspirate and/or biopsy and/or endogenous BFU-E culture&#xD;
&#xD;
          -  Abdominal ultrasound&#xD;
&#xD;
          -  Lung function tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François GIRODON</last_name>
    <phone>0380293031</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.girodon@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GIRODON</last_name>
      <phone>03 80 29 30 31</phone>
      <phone_ext>+33</phone_ext>
      <email>francois.girodon@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane BEZIEAU</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

